Abstract:
The clinical manifestations of COVID-19 disease are mainly caused by an irregular host response associated with excessive expression of inflammatory markers. Patients with mild, moderate, and severe symptoms of COVID-19 with or without comorbidities use a combination of antiviral drugs and antibiotics. This study aimed to determine the relationship between the use of antiviral drugs and antibiotics on the clinical outcomes of COVID-19 patients. The research design used a cross-sectional study with retrospective data collection. The inclusion criteria were COVID-19 patients hospitalized at Panti Waluya Sawahan Malang Hospital with or without comorbidities, positive RT-PCR results, and receiving antibiotic and antiviral therapy. The clinical outcome is a patient improvement if the length of stay is 14 days, and the patient worsens if it is >14 days. There is no relationship between antibiotics and antiviral drugs on the clinical outcomes of COVID-19 patients (p>0,05).
Highlights:
- Excessive expression of inflammatory markers contributes to the clinical manifestations of COVID-19.
- Combination therapy of antiviral drugs and antibiotics is commonly used for COVID-19 patients.
- The study found no significant relationship between the use of antibiotics and antiviral drugs and the clinical outcomes of COVID-19 patients
Keywords: antibiotics, antiviruses, COVID-19, clinical improvement, clinical deterioration
References
S. Setiati dan MK Azwar, “COVID-19 and Indonesia,” dalam Proc. Konferensi Internasional tentang Penyakit Menular (ICID), 2020, hlm. 1-5.
MN Hasan et al., "Tingkat fatalitas kasus global COVID-19 telah menurun sejak Mei 2020," Am. J. Trop. Kedokteran Hyg., vol. 104, tidak. 6, hlm. 2176-2184, Juni 2021, doi: 10.4269/ajtmh.20-1496.
G. Deng, M. Yin, X. Chen, dan F. Zeng, "Penentu klinis untuk kematian 44.672 pasien COVID-19," Crit. Peduli, vol. 24, tidak. 1, 28 April 2020, doi: 10.1186/s13054-020-02902-w.
G. Lippi, C. Mattiuzzi, F. Sanchis-Gomar, dan BM Henry, "Karakteristik klinis dan demografi pasien yang meninggal akibat COVID-19 di Italia vs China," J. Med. Virol., vol. 92, tidak. 10, hlm. 1759-1760, Oktober 2020, doi: 10.1002/jmv.25860.
H. Surendra et al., "Karakteristik klinis dan mortalitas terkait COVID-19 di Jakarta, Indonesia: Studi kohort retrospektif berbasis rumah sakit," Lancet Reg. Health West Pac., vol. 9 April 2021, doi: 10.1016/j.lanwpc.2021.100108.
R. Yulia et al., "Evaluasi Efektivitas Obat Antibakteri dan Antivirus dalam Terapi COVID-19: Pendekatan Retrospektif Berbasis Data," Patofisiologi, vol. 29, tidak. 1, hlm. 92-105, Maret 2022, doi: 10.3390/patofisiologi29010009.
M. Rodriguez-Guerra, P. Jadhav, dan TJ Vittorio, "Pengobatan saat ini pada penyakit COVID-19: tinjauan cepat," Drugs Context, vol. 10 Februari 2021, doi: 10.7573/DIC.2020-10-3.
GJ Baracco, "Penggunaan Remdesivir dan Lama Menginap di Rumah Sakit - Paradoks Uji Coba Klinis vs Penggunaan di Kehidupan Nyata," JAMA Network Open, vol. 4, tidak. 7, 15 Juli 2021, doi: 10.1001/jamanetworkopen.2021.16057.
JH Beigel et al., "Remdesivir untuk Pengobatan Covid-19 — Laporan Akhir," New England Journal of Medicine, vol. 383, tidak. 19, hlm. 1813-1826, November 2020, doi: 10.1056/nejmoa2007764.
ES Rosenberg et al., "Asosiasi Pengobatan dengan Hydroxychloroquine atau Azitromisin dengan Kematian di Rumah Sakit pada Pasien dengan COVID-19 di Negara Bagian New York," JAMA - J. Am. Kedokteran Asosiasi, vol. 323, tidak. 24, hlm. 2493-2502, Juni 2020, doi: 10.100